Provides home respiratory therapies, including oxygen equipment and ventilators. Offers obstructive sleep apnea therapy devices, such as CPAP and BiPAP machines. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
No real growth (2% a year).
The gap is $229.6M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Our checks did not surface a specific strength to highlight here.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The price action doesn’t yet back an upward turn. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.